CHECKMATE PHARMACEUTICALS SKIN

The transaction is expected to be complete by mid-2022. Checkmate Pharmaceuticals has proposed terms for a 75 million U.S. Once the acquisition is successfully closed, Regeneron will gain all shares not acquired in the tender through a second-step merger. Vidutolimod has not been approved by the US Food and Drug Administration (FDA) or any other regulatory agency but through the acquisition, Regeneron will use its resources to accelerate its development. It is administered into the tumor and Checkmate claims it induces and expands anti-tumor T cells and tumor regression as a monotherapy in patients whose tumors have previously progressed on PD-1 checkpoint inhibition. Once activated by vidutolimod by the various signals, pDC recruits and coordinates a wide range of immune cells, producing a strong anti-tumor T cell response. Then, a signal is sent to pDC and this brings the CpG-A to TLR9 inside the pDC and the CpG-A stimulates TLR9, which brings increased levels of type I interferons resulting in stronger anti-tumor T cell response. is a clinical stage biotechnology company focused on developing its proprietary technology to harness the power of the immune. Vidutolimod works by activating an immune response to the VLP, which leads to the production of antibodies that transfer the VLP into plasmacytoid dendritic cells (Pdc) as well as other immune cells using receptors called FcR. “The unique combination of a differentiated Toll-like receptor 9 with other antibody-based oncology agents may result in increased clinical benefit and provide new treatment options for patients in need.” Checkmate’s product candidate, CMP-001, is a differentiated TLR9 agonist delivered as a biologic virus-like particle designed to trigger. “As we continue to advance and expand our research efforts in immuno-oncology, the acquisition of Checkmate will add a promising new modality to Regeneron’s toolkit of potential approaches for difficult-to-treat cancers,” said Leonard Schleifer, CEO of Regeneron. About Checkmate Pharmaceuticals Checkmate Pharmaceuticals is a clinical stage biotechnology company focused on developing proprietary technology to harness the power of the immune system to combat cancer.

CHECKMATE PHARMACEUTICALS SKIN

He has published more than 250 scientific papers (h-index = 125), and is an inventor on >50 issued US patents covering oligonucleotide technologies.Vidutolimod is being studied in combinational with other agents for head and neck cancer, melanoma, and non-melanoma skin cancers. Art left academia and joined Coley full-time in 2001. He has had 19 years of patient care experience, although his focus has always been on basic research and teaching. He was a Staff Fellow at the NIH in the Arthritis Institute from 1986 to 1991, when he joined the University of Iowa, becoming Professor of Internal Medicine in the Division of Rheumatology. The clinical programs are focused on enabling more people with cancer to benefit from the promise of novel immunotherapies. He is a Professor in the University of Massachusetts RNA Therapeutics Institute and he serves on the scientific advisory boards of several companies developing oligonucleotide therapeutics.Īrt graduated from Haverford College in 1979, received his MD from Washington University in 1983, and completed a residency in Internal Medicine at the University of Minnesota in 1986. Checkmate Pharma is a clinical-stage biopharmaceutical company developing a new approach for cancer immunotherapy. Art co-founded the first antisense journal, Nucleic Acid Therapeutics, which he edited for 16 years, and the Oligonucleotide Therapeutics Society, for which he recently served as President. Based on this technology he co-founded Coley Pharmaceutical Group in 1997, discovering and taking 4 novel oligonucleotides into clinical development.

Art discovered the immune stimulatory CpG DNA motif in 1994, which led to a new approach to immunotherapy and vaccine adjuvants. Prior to that role Art was CSO at Sarepta until July 2014 co-founder and CEO at RaNA Therapeutics from 2011 to 2013 CSO of Pfizer’s Oligonucleotide Therapeutics Unit from 2008 to 2011 and co-founder, CSO of Coley Pharmaceutical Group from 1997 until its acquisition and incorporation into Pfizer in 2008. Most recently he founded Checkmate Pharmaceuticals to develop novel oligonucleotides for cancer immunotherapy, where he currently serves as CSO. Krieg, MD has worked in the oligonucleotide field since the 1980s.

Checkmate pharmaceuticals